The authors reply
- PMID: 37589525
- DOI: 10.1097/CCM.0000000000005946
The authors reply
Conflict of interest statement
The authors have disclosed that they do not have any potential conflicts of interest.
Comment on
-
Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Acute, Severe Illness: Has the Time Come to Administer Them in the Acute Setting?Crit Care Med. 2023 Sep 1;51(9):e185-e186. doi: 10.1097/CCM.0000000000005934. Epub 2023 Aug 17. Crit Care Med. 2023. PMID: 37589524 No abstract available.
References
-
- Patoulias D: Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Acute, Severe Illness: Has the Time Come to Administer Them in the Acute Setting? Crit Care Med. 2023; 51:e185–e186
-
- Ng PY, Ng AK, Ip A, et al.: Risk of ICU admission and related mortality in patients with sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors: A territory-wide retrospective cohort study. Crit Care Med. 2023; 51:1074–1085
-
- Rudd KE, Johnson SC, Agesa KM, et al.: Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study. Lancet. 2020; 395:200–211
-
- Lamontagne F, Masse MH, Menard J, et al.; LOVIT Investigators and the Canadian Critical Care Trials Group: Intravenous vitamin C in adults with sepsis in the intensive care unit. N Engl J Med. 2022; 386:2387–2398
-
- Theofilis P, Sagris M, Oikonomou E, et al.: The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. Int Immunopharmacol. 2022; 111:109080
Publication types
LinkOut - more resources
Full Text Sources
